NEW DRUG DEVELOPMENT IN LYMPHOMA OF CHINA IS GOING GLOBAL

In 2018, China contributed to 7.8% of the global drug innovation pipeline and 11.6% new launches, thereby becoming largest base for R&D in Asia. Statistically, oncology, particularly field lymphoma, occupies major area innovative development. Despite substantial advances, there is still an unmet need develop better therapies B-cell lymphomas (BCL), especially those incurable settings. As icon successful China, Zanubrutinib, known as Best-in-class BTK inhibitor, exhibits more potent kinase selectivity less off-target toxicites than other inhibitors. two phase 3 head-to-head trials against ibrutinib, Zanubrutinib showed superior ORR PFS R/R CLL/SLLpatients, deeper durable responses WM patients. Of note, plus obinutuzumab was associated with improved compared alone FL acccording ROSEWOOD trial. Moreover, rituximab versus bendamustine undergoing Phase III trial transplant-ineligible, untreated MCL. To date, has been approved 60+ markets across 4 lead indications (CLL/SLL, WM, MCL, MZL) pursuing approval a broader range worldwide. The BCL-2 inhibitor lisaftoclax (APG-2575) shown high activity favorable security monotherapy combination or acalabrutinib patients treatment-naïve, CLL/SLL from 2 study. PSB202 first-in-class bifunctional antibody that target CD20 CD37 treatment BCL. It expected elicit efficacy reduce resistance/refractivity initial treatment. A I study evaluating safety previously treated, relapsed, indolent BCL progress. emergence these drugs offers possibilities explore novel combinations addition BCL, I/II demonstrates antitumor managable Golidocitinib, selective JAK1 PTCL. From participation leadership, best class first class, evolved one market development globally, potential shape way future Keyword: molecular targeted No conflicts interests pertinent abstract.